This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Stocks in Motion

Updated from 2:30 p.m. EDT

Shares of aaiPharma (AAII) were among the worst-performing health and pharmaceutical stocks Friday, falling 18.1% after the company said it would not be able to make its $10 million interest payment scheduled for today.

Lenders have granted the drugmaker a 30-day grace period, but if the company fails to make the payment by Oct. 31 it will be in default. The company said there is a likelihood that it will be in default of certain covenants under its senior credit facility; the company is seeking waivers and consents for these defaults. Shares traded down 28 cents to $1.27.

Cyberonics (CYBX) fell 7.9% after Advanced Neuromodulation Systems (ANSI) dropped its $22-a-share offer for the company. "We are disappointed that the Cyberonics board of directors has chosen to reject our invitation to discuss a business combination," ANSI said. ANSI, which owns about 14.7% of Cyberonics, will continue to manage its investment as a shareholder, saying "we genuinely wish Cyberonics the best as it works toward fulfilling its mission." Shares of Cyberonics traded down $1.61 to $18.85. Shares of ANSI traded up 52 cents to $30.87.

Shares of Nastech Pharmaceutical (NSTK) fell 8.3% after the company filed an $80 million shelf registration statement with the Securities and Exchange Commission. The pharmaceutical company said that proceeds from any future products would be used for general corporate purposes. Shares traded down $1.18 to $13.11.

eResearchTechnology (ERES) fell 2.8% after it lowered its third-quarter financial outlook and warned that results would miss expectations. The company now expects earnings of 13 cents to 14 cents a share on sales of $27 million to $28 million. Previously, it forecast earnings of 16 cents to 17 cents a share on sales of $30 million to $30.5 million. Analysts polled by Thomson First Call had expected earnings of 16 cents a share on sales of $30.7 million. Third-quarter results were hurt by delays in phase I studies, the company said.

Looking ahead, eResearch now expects full-year earnings 58 cents to 60 cents a share on sales of $112 million to $115 million. Previously, it forecast earnings of 62 cents to 63 cents a share on sales of $117 million to $119 million. Analysts had expected earnings of 61 cents a share on sales of $118.8 million. Shares traded down 37 cents to $12.96.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs